Cells have evolved a complex network of biochemical pathways, collectively known as the
DNA damage response (DDR), to prevent detrimental mutations from being passed on to …

Develo** novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance
is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical …

Mutations in BRCA1 or BRCA2 (BRCA) is synthetic lethal with poly (ADP-ribose)
polymerase inhibitors (PARPi). Lethality is thought to derive from DNA double-stranded …

To identify approaches to target DNA repair vulnerabilities in cancer, we discovered
nanomolar potent, selective, low molecular weight (MW), allosteric inhibitors of the …

Many clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-
associated protein 9 (Cas9)-based genome editing technologies take advantage of Cas …

DNA double-strand breaks (DSBs) are cytotoxic lesions that threaten genome integrity and
cell viability. Typically, cells repair DSBs by either nonhomologous end joining (NHEJ) or …

The major pathways of DNA double-strand break (DSB) repair are crucial for maintaining
genomic stability. However, if deployed in an inappropriate cellular context, these same …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …